Abstract Details

Title Annual Costs Associated with Patients with Migraine by Intensity of Treatment-Seeking Behavior

Topic Headache

Presentation(s) P12 - Poster Session 12 (12:00 PM-1:00 PM)

Poster/Presentation
Number 7-001

Objective To evaluate all-cause and migraine-specific healthcare costs associated with patients with migraine by different intensities of treatment-seeking behavior.

Background Few analyses have evaluated the incremental economic burden of migraine on the healthcare system in increasing treatment-seeking behavior.

Design/Methods Retrospective analysis of administrative claims using IBM MarketScan® Commercial and Medicare Research Databases from 1/1/2016 through 12/31/2017 was conducted with the index date of 1/1/2017. Adult patients with ≥1 migraine medical claim in pre-index year (2016), with continuous enrollment throughout study period, and without malignancy were eligible. Annual all-cause and migraine-specific post-index year (2017) costs were evaluated using multivariate regression techniques controlling for demographics and baseline clinical characteristics. Patients were stratified by intensity of treatment-seeking behavior observed in pre-index year based on combinations of utilization of outpatient (OP) and inpatient (IP) services, and acute (ARx) and preventive (PRx) migraine medications.

Results 338,584 patients (mean age, 44 years; 82% female) met the study criteria. Most common comorbidities included non-headache pain (64%), hypertension (26%), and anxiety (23%). Adjusted mean all-cause annual costs ranged from $6,620 in OP-only cohort to $30,759 in OP+IP with/out (±) ARx cohort. Use of OP+ARx and/or OP+PRx was associated with increased all-cause costs from $9,637 to $17,742 compared to OP-only cohort. All-cause costs were $20,338 with use of IP±ARx and/or IP+PRx and were highest at $30,759 with the use of OP+IP±ARx. Adjusted mean annual migraine-specific costs ranged from $658 to $5,193 in OP-only and IP±ARx and/or IP±PRx cohorts, respectively. OP+IP±ARx was associated with the second-highest migraine-specific cost ($4,575).

Conclusions Increases in intensity of treatment-seeking behavior, as defined by use of migraine-specific medical and pharmacy services, were generally associated with incremental rises in annual healthcare expenditures, including all-cause and migraine-specific costs. Effective migraine prevention therapies have the potential to reduce the treatment-seeking behavior intensity and, therefore, associated economic migraine burden.

Authors/Disclosures
Steven Kymes PRESENTER	Steven Kymes has received personal compensation for serving as an employee of Lundbeck. Steven Kymes has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Ophthalmology. Steven Kymes has received research support from Emmes Corporation.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details